Analysts Set Compass Therapeutics, Inc. (NASDAQ:CMPX) PT at $11.77

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) have been given an average recommendation of “Moderate Buy” by the sixteen brokerages that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $11.7692.

Several equities research analysts recently issued reports on the company. D. Boral Capital reiterated a “buy” rating and set a $30.00 price target on shares of Compass Therapeutics in a report on Monday, April 27th. Stifel Nicolaus set a $6.00 price objective on Compass Therapeutics in a research note on Monday, June 1st. Citigroup reaffirmed a “market outperform” rating on shares of Compass Therapeutics in a report on Thursday, June 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Therapeutics in a research note on Friday, July 17th. Finally, Piper Sandler increased their target price on shares of Compass Therapeutics from $4.00 to $6.00 and gave the company an “overweight” rating in a report on Friday, August 7th.

Compass Therapeutics Stock Performance

CMPX stock opened at $2.40 on Friday. The business has a 50-day simple moving average of $2.14 and a two-hundred day simple moving average of $3.60. The company has a market capitalization of $432.21 million, a P/E ratio of -6.00 and a beta of 0.92. Compass Therapeutics has a 52-week low of $1.61 and a 52-week high of $6.88.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). As a group, sell-side analysts forecast that Compass Therapeutics will post -0.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Compass Therapeutics

A number of institutional investors have recently added to or reduced their stakes in CMPX. AXQ Capital LP lifted its position in shares of Compass Therapeutics by 68.1% during the 2nd quarter. AXQ Capital LP now owns 42,118 shares of the company’s stock worth $92,000 after buying an additional 17,060 shares in the last quarter. Two Sigma Securities LLC purchased a new position in shares of Compass Therapeutics in the 2nd quarter worth approximately $64,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Compass Therapeutics by 27.3% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 177,814 shares of the company’s stock valued at $389,000 after acquiring an additional 38,172 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Compass Therapeutics by 5.2% in the second quarter. Wellington Management Group LLP now owns 378,687 shares of the company’s stock valued at $829,000 after acquiring an additional 18,562 shares in the last quarter. Finally, Palo Alto Investors LP purchased a new stake in shares of Compass Therapeutics during the second quarter valued at approximately $12,771,670,000. 68.43% of the stock is owned by institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.